Comparative Efficacy of Bone Defect Filler Strategies Following Lesion Debridement for Osteonecrosis of the Femoral Head: A Systematic Review and Network Meta‐Analysis Authors: Zukang Miao, Zhiwei Pei, Bing Wang, Zemeng Hou, Jingkun Jia, Junfei Zhao, Jing Dai, Xiaolei Sun, Xinlong Ma Published: 2026 ABSTRACT ABSTRACTObjectiveThis study aimed to systematically review and compare the clinical and radiographic outcomes of different bone defect filler materials following lesion debridement for osteonecrosis of the femoral head (ONFH). Existing evidence on filler materials relies heavily on isolated pairwise comparisons, leaving the optimal reconstruction strategy undefined. Therefore, the current network meta‐analysis integrates multiple treatments and diverse clinical endpoints to determine the most effective reconstructive option. With increasing recognition of the importance of intraosseous structural reconstruction, this study sought to provide evidence‐based guidance for filler selection in hip‐preserving treatment.MethodsPubMed, MEDLINE, Embase, the Cochrane Library, Web of Science, and Scopus were searched from inception to March 2026. Comparative clinical studies evaluating two or more bone defect filler materials after lesion debridement for ONFH were included. Evidence was synthesized using a Bayesian random‐effects network meta‐analysis. Methodological quality and risk of bias were assessed using the Cochrane Risk of Bias Tool 2.0 for randomized controlled trials (RCTs) and a modified Newcastle–Ottawa Scale for non‐randomized comparative trials (NCTs).ResultsAfter screening 2046 records, 18 eligible studies were included, comprising 10 RCTs and 8 NCTs, with a total of 1176 patients and 1284 hips. Fourteen filler strategies were analyzed, including without graft, allograft, tantalum rods, iliac autograft, artificial bone, fibular autograft, vascularized iliac autograft, vascularized fibular autograft, artificial bone combined with iliac autograft, tantalum rods combined with autograft or allograft, other autografts, other autografts combined with vascularized greater trochanter graft, iliac autograft with screw fixation, and vascularized iliac autograft with screw fixation. Tantalum rods combined with bone graft showed relative advantages in functional recovery and pain relief, as assessed by the Harris Hip Score and Visual Analogue Scale. However, tantalum rods alone were associated with a higher rate of conversion to total hip arthroplasty. Allograft ranked favorably for early functional recovery and necrosis stage maintenance, although no significant differences were observed among interventions for necrosis stage maintenance. Iliac autograft with screw fixation ranked first in preventing radiographic progression. However, without significant pairwise differences, this ranking remains inconclusive.ConclusionConsidering postoperative functional recovery, pain relief, and disease progression after lesion debridement, tantalum rods combined with bone graft may provide advantages in early outcomes, but the long‐term failure risk of tantalum rods alone should be carefully considered. Allograft and iliac autograft with screw fixation showed favorable profiles in specific outcome domains and may represent balanced options in selected patients. Further high‐quality studies with longer follow‐up are needed to validate the long‐term efficacy of different filler strategies. Abbreviations artificial bone+autograft iliac autograft iliac +screw assessing the methodological quality of systematic reviews association research circulation osseous autograft other+autograft vascularized greater trochanter Harris Hip Scoring System non‐randomized comparative trials network meta‐analysis necrosis staging maintained osteonecrosis of the femoral head preferred reporting items for systematic reviews and meta‐analyses randomized controlled trials radiographic progression receive total hip arthroplasty tantalum rods tantalum rods+autograft/allograft Visual Analogue Scale autograft vascularized fibular autograft vascularized iliac autograft vascularized iliac+screw Introduction Osteonecrosis of the femoral head (ONFH) is a progressive hip disease characterized by pain, restricted motion, and structural deterioration of the femoral head [1]. Abnormal repair and remodeling of trabecular bone lead to structural changes or collapse of the femoral head. Once femoral head collapse occurs, total hip arthroplasty (THA) is often required [2, 3]. Because ONFH commonly affects young and active patients, effectively restoring structural support within the bone before collapse remains a major goal of treatment [4, 5, 6]. Thorough debridement of necrotic bone, achieved via techniques such as core decompression or surgical hip dislocation, remains the primary hip‐preserving strategy to halt disease progression [7, 8, 9]. However, debridement also leaves an intraosseous defect. Without effective reconstruction, this defect may further weaken the subchondral bone and increase the risk of collapse [10]. Therefore, restoring structural support within the femoral head is essential after lesion debridement. Various filler materials have been used to reconstruct the bone defect, including vascularized and non‐vascularized autografts, allografts, artificial bone substitutes, and tantalum rods [8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]. These materials differ in mechanical strength, biological activity, surgical morbidity, and long‐term stability. Cancellous bone grafting may promote vascular ingrowth and bone remodeling, but its mechanical support is limited [27]. Tantalum rods provide immediate structural reinforcement and load transfer, but single‐rod implantation may not adequately support the entire necrotic zone and may complicate later revision [28, 29]. Thus, the optimal filler strategy remains uncertain, and no single material appears to fully meet both the mechanical and biological demands of intraosseous reconstruction. Current evidence is mainly derived from single‐center studies with small sample sizes. Most previous analyses have focused on selected material types or pairwise comparisons, which limits direct evaluation of the relative efficacy of multiple filler strategies [30]. Network meta‐analysis (NMA) can integrate direct and indirect evidence and rank different interventions within a unified analytical framework [31]. This approach is particularly suitable for comparing multiple filler materials when head‐to‐head evidence is limited. Therefore, this study performed a Bayesian random‐effects NMA to compare bone defect filler strategies following lesion debridement for ONFH. We evaluated functional recovery, pain relief, necrosis stage maintenance, radiographic progression, and conversion to THA. By comparing a broad range of filler strategies, this study aims to clarify their relative advantages and provide evidence for individualized material selection in hip‐preserving surgery. Materials and Methods Review Protocol This systematic review and network meta‐analysis was conducted according to the PRISMA 2020 extension statement for network meta‐analyses [32]. The aim was to compare the clinical and radiographic outcomes of different bone defect filler materials in patients with ONFH undergoing lesion debridement for hip preservation. The study protocol has been registered on the PROSPERO platform (CRD420261389774). Search Strategy PubMed, MEDLINE, Embase, the Cochrane Library, Web of Science, and Scopus were searched from database inception to March 2026. The search strategy combined Medical Subject Headings (MeSH) and free‐text words using Boolean operators. The specific search query was constructed as follows: (“Femur Head Necrosis”[MeSH] OR “osteonecrosis of the femoral head” OR “femoral head necrosis” OR “femoral head avascular necrosis”) AND (“Bone Transplantation”[MeSH] OR “Bone Substitutes”[MeSH] OR “bone void filler” OR “filling material” OR “bone graft”). The reference lists of relevant studies were also manually screened to identify additional eligible articles. The search was performed independently by two investigators, and disagreements were resolved by discussion with a senior reviewer. Eligibility Criteria Studies were included if they met the following criteria: Comparative clinical studies including patients with isolated ONFH who underwent lesion debridement;Comparison of two or more bone defect filler materials;Available baseline information, including age, sex, body mass index (BMI), ONFH stage, debridement method, and filler type;Reporting of at least one eligible clinical or radiographic outcome, including Harris Hip Score (HHS), Visual Analogue Scale (VAS), Necrosis Staging Maintained (NSM), Radiographic Progression (RP), or Receive Total Hip Arthroplasty (RTHA);A minimum follow‐up of 12 months. Comparative clinical studies including patients with isolated ONFH who underwent lesion debridement; Comparative clinical studies including patients with isolated ONFH who underwent lesion debridement; Comparison of two or more bone defect filler materials; Comparison of two or more bone defect filler materials; Available baseline information, including age, sex, body mass index (BMI), ONFH stage, debridement method, and filler type; Available baseline information, including age, sex, body mass index (BMI), ONFH stage, debridement method, and filler type; Reporting of at least one eligible clinical or radiographic outcome, including Harris Hip Score (HHS), Visual Analogue Scale (VAS), Necrosis Staging Maintained (NSM), Radiographic Progression (RP), or Receive Total Hip Arthroplasty (RTHA); Reporting of at least one eligible clinical or radiographic outcome, including Harris Hip Score (HHS), Visual Analogue Scale (VAS), Necrosis Staging Maintained (NSM), Radiographic Progression (RP), or Receive Total Hip Arthroplasty (RTHA); A minimum follow‐up of 12 months. A minimum follow‐up of 12 months. Exclusion criteria encompassed: Involved additional biological or surgical interventions, such as platelet‐rich plasma, stem cell therapy, or rotational osteotomy;Conference abstracts, editorials, reviews, case reports, and other gray literature. Involved additional biological or surgical interventions, such as platelet‐rich plasma, stem cell therapy, or rotational osteotomy; Involved additional biological or surgical interventions, such as platelet‐rich plasma, stem cell therapy, or rotational osteotomy; Conference abstracts, editorials, reviews, case reports, and other gray literature. Conference abstracts, editorials, reviews, case reports, and other gray literature. Study Selection Titles and abstracts were first screened to remove irrelevant records. Potentially eligible studies were then assessed by full‐text review. Two investigators independently completed the screening process. Any disagreement was resolved by discussion with a third senior investigator. Data Extraction Data were extracted using a predefined form. The following information was collected: study characteristics, including author, year, country, study design, evidence level, follow‐up duration, randomization, blinding, and loss to follow‐up; patient characteristics, including sample size, age, sex, BMI, ONFH etiology, and ARCO or Ficat stage; intervention details, including debridement method, surgical approach, filler material, postoperative weight‐bearing protocol, and pharmacological treatment; and eligible outcome data. Data extraction was performed independently by two investigators and checked by a third reviewer. Risk of Bias Assessment The risk of bias in randomized controlled trials was assessed using the Cochrane Risk of Bias Tool 2.0. The methodological quality of non‐randomized comparative trials was evaluated using a modified Newcastle–Ottawa Scale. All assessments were conducted independently by three investigators. Discrepancies were resolved by consensus. Outcome Measures The evaluated outcomes included HHS at 6‐month and 1‐year follow‐up, VAS pain score, NSM, RP, and RTHA. NSM was defined as maintenance of the preoperative ARCO or Ficat stage at final follow‐up. RP was defined as radiographic evidence of femoral head collapse or progression of the necrotic lesion. RTHA was defined as conversion to total hip arthroplasty during follow‐up and was regarded as clinical failure. Extreme long‐term follow‐up data were excluded from cumulative survival networks to minimize late‐stage reporting bias. The individual hip joint served as the primary unit of analysis for all clinical and radiographic outcomes, as surgical interventions and defect reconstruction were performed and evaluated on a per‐hip basis. Data Synthesis and Statistical Analysis A Bayesian random‐effects network meta‐analysis (NMA) was conducted within a generalized linear model (GLM) framework using the R package multinma [33]. Network evidence plots were generated to illustrate inter‐intervention comparative structures. Mean differences (MDs) with 95% credible intervals (CrIs) were calculated for continuous outcomes (6‐month and 1‐year Harris Hip Score, Visual Analogue Scale), while odds ratios (ORs) with 95% CrIs were computed via a logit link function for binary outcomes (Necrosis Staging Maintained, Radiographic Progression, and Receive Total Hip Arthroplasty). Continuity corrections (+0.5) were applied to zero‐event arms where appropriate. Bayesian parameter estimation was performed using Markov Chain Monte Carlo (MCMC) sampling with four independent chains (50,000 iterations per chain; 10,000 warm‐up iterations; thinning interval of 10, yielding 16,000 posterior samples). Minimally informative priors were specified for treatment effects [N0,1002] and between‐study heterogeneity [Half‐Normal (0, 12) for τ]. Convergence was confirmed quantitatively via Gelman–Rubin diagnostics (all R`<1.05) and visually via trace plots. Model goodness‐of‐fit and parsimony were assessed using residual deviance and the Deviance Information Criterion (DIC), with between‐study heterogeneity quantified by posterior τ2 estimates. Intervention hierarchies were derived using the surface under the cumulative ranking curve (SUCRA) and posterior rank probabilities, with higher values indicating greater efficacy. Treatment rankings were strictly interpreted alongside point estimates and 95% CrIs rather than as standalone metrics. Statistical significance was defined as 95% CrIs excluding null values (0 for MDs, 1 for ORs). Local inconsistency between direct and indirect evidence was evaluated using node‐splitting models in closed loops (p<0.05 indicating significance). Potential small‐study effects and publication bias were assessed only when at least 10 sufficiently comparable studies were available, using comparison‐adjusted funnel plots and Egger's regression. Outcomes with fewer studies or sparse direct comparisons were not formally tested because funnel‐plot asymmetry is unreliable under these conditions. To evaluate potential selection bias from non‐randomized designs, a sensitivity analysis was conducted by restricting the Bayesian network exclusively to randomized controlled trials (RCTs). Assessment of Transitivity To ensure the validity of indirect comparisons within the Bayesian network, the transitivity assumption was evaluated by comparing the distribution of potential effect modifiers across treatment arms. Potential effect modifiers included patient age, sex ratio, baseline BMI, ONFH etiology (steroid‐induced, alcohol‐induced, or idiopathic), and disease stage (ARCO/Ficat Stage I–III). Clinical transitivity was considered plausible if these baseline variables were similarly distributed across treatment nodes, ensuring that patients in one comparison group could hypothetically have been randomized to any other treatment arm within the network. Results Baseline Characteristics of Included Studies The initial search identified 2046 records. After title and abstract screening, 98 full‐text articles were assessed for eligibility. Finally, 18 studies met the inclusion criteria, including 10 randomized controlled trials (RCTs; 632 patients, 689 hips) and 8 non‐randomized comparative trials (NCTs; 544 patients, 595 hips). Among them, 15 studies were conducted in China, two in India, and one in Egypt. Overall, 1176 patients involving 1284 hips were included in the network meta‐analysis, as shown in Figure 1. Flow diagram of study selection. Fourteen bone defect filler strategies were evaluated: without graft (156 hips), allograft (40 hips), tantalum rods (Ta Rods, 159 hips), iliac autograft (177 hips), artificial bone (178 hips), fibular autograft (125 hips), vascularized iliac autograft (VI Autograft, 55 hips), vascularized fibular autograft (VF Autograft, 69 hips), iliac autograft combined with artificial bone (AI+AB, 22 hips), tantalum rods combined with autograft or allograft (Ta Rods+Graft, 50 hips), other autografts (130 hips), other autografts combined with vascularized greater trochanter autograft (Autograft Other+VGT, 84 hips), iliac autograft with screw fixation (AI+Screw, 16 hips), and vascularized iliac autograft with screw fixation (VI Autograft+Screw, 23 hips). The mean age was 35.0 years (range, 29.9–45.0), the proportion of female patients was 38.0% (range, 10.5%–58.4%), and the mean baseline BMI was 24.3 kg/m2 (range, 22.1–28.6). The median follow‐up duration was 35.4 months (range, 12.0–94.3). The baseline characteristics of the included studies are summarized in Tables 1 and S1. TABLE 1Baseline characteristics of the included studies.Study characteristicsMedian/No. (%)IQRRangeEligible studiesTotal number of RCTs10——Total number of NCTs8——Number of participants (Hips)1176 (1284)——Median follow‐up, months35.418–40.312–94.3RegionIndia2 (11.11)——Egypt1 (5.56)——China15 (83.33)——ParticipantsMean age, years35.031.9–36.829.9–45.0Percentage of females (%)38.023.8–50.010.5–58.4Baseline mean BMI24.322.6–25.322.1–28.6ARCO/Ficat stageStage I84——StageII814——Stage III217——Stage IV2——EtiologyNon‐traumatic1186——Traumatic27——Abbreviations: BMI, body mass index; IQR, interquartile range; NCT, nonrandomized comparative trials; RCT, randomized controlled trial. Baseline characteristics of the included studies. Abbreviations: BMI, body mass index; IQR, interquartile range; NCT, nonrandomized comparative trials; RCT, randomized controlled trial. The overall risk of bias in the included RCTs raised some concerns, mainly because blinding was difficult in surgical trials. The methodological quality of the included NCTs was acceptable, with a median Newcastle–Ottawa Scale score of 6. Detailed quality and risk‐of‐bias assessments are provided in Table S2 and Figure S1. Assessment of Publication Bias A formal evaluation of publication bias was statistically impractical across all assessed outcomes. For instance, while the 12‐month HHS network comprised 15 studies, the data was highly fragmented across 14 distinct filler strategies without a universal reference treatment. This left most direct comparisons with three or fewer studies. Because all other clinical endpoints were based on fewer than 10 studies, generating comparison‐adjusted funnel plots or applying regression‐based asymmetry tests would lack statistical power. Consequently, the presence of potential publication bias cannot be definitively ruled out. The distribution of potential effect modifiers across the 14 treatment strategies is detailed in Table S3. Overall, key baseline parameters—such as median node‐level mean age (35.0 years, IQR: 31.9–36.8 years), proportion of female patients, non‐traumatic etiology dominance (> 90%), and the predominance of pre‐collapse/early‐collapse lesions (ARCO/Ficat Stages I–III)—were broadly comparable across treatment arms, supporting the validity of the transitivity assumption for indirect comparisons. Comparative Outcomes of Different Bone Defect Filler Materials Harris Hip Score (HHS) at 6‐Month Follow‐Up The Harris Hip Score (HHS) was used to assess early postoperative hip function [34]. The network structure and pairwise comparisons for 6‐month HHS are shown in Figure 2A,B. Compared with the no‐graft group, artificial bone, iliac autograft, other autografts, tantalum rods, and vascularized iliac autograft did not show superior functional recovery. In contrast, allograft, fibular autograft, and vascularized fibular autograft were associated with better 6‐month HHS. Network meta‐analysis of bone defect filler strategies based on HHS at 6‐month follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. Regarding early functional recovery at 6‐month follow‐up, allograft ranked first (SUCRA = 100.0%), demonstrating a statistically significant functional improvement compared with others (MD = 10.78, 95% CrI: 6.17 to 15.39). Subsequent rankings included vascularized fibular (VF) autograft, vascularized iliac autograft combined with screw fixation, fibular autograft, tantalum rods, artificial bone, without‐graft, other autografts, iliac autograft, and standalone vascularized iliac autograft (Figure 2C–E). Overall, these findings suggest that allograft and vascularized fibular graft‐based strategies may provide more favorable early functional recovery after lesion debridement. A sensitivity analysis restricted to RCTs yielded consistent ranking profiles for 6‐month HHS, as detailed in Figure S2A–E. Harris Hip Score (HHS) at 1‐Year Follow‐Up The 1‐year HHS was used to evaluate medium‐term functional recovery after hip‐preserving surgery. The network structure and pairwise comparisons are shown in Figure 3A,B. Compared with the no‐graft group, artificial bone, fibular autograft, iliac autograft, and other autografts were associated with lower 1‐year HHS, suggesting less favorable functional recovery. Network meta‐analysis of bone defect filler strategies based on HHS at 1‐year follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. For functional recovery at 1‐year follow‐up, tantalum rods combined with bone graft ranked first (SUCRA = 99.9%), demonstrating a statistically significant functional improvement (MD = 20.47, 95% CrI: 11.60 to 29.34). Subsequent rankings included the allograft, iliac autograft combined with screw fixation, without‐graft group, artificial bone combined with iliac autograft, tantalum rods alone, artificial bone, vascularized fibular autograft, vascularized iliac autograft with screw fixation, iliac autograft, fibular autograft, vascularized iliac autograft, other autografts combined with vascularized greater trochanter graft, and other autografts (Figure 3C–E). Sensitivity analysis incorporating RCTs alone demonstrated high consistency with these 1‐year functional outcomes across network structure and ranking distributions (Figure S3A–E). The credible intervals of direct and indirect comparisons largely overlapped, and all p values were greater than 0.05, indicating no significant local inconsistency (Figure S4). Prognostic Analysis of Visual Analogue Scale Pain Score (VAS) The Visual Analogue Scale (VAS) was used to assess postoperative pain at final follow‐up, with lower scores indicating less pain [35]. Compared with the other filler strategies, tantalum rod‐based treatment was associated with lower VAS scores, suggesting better pain relief after lesion debridement (Figure 4A,B). Network meta‐analysis of bone defect filler strategies based on VAS at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. In terms of pain relief, tantalum rods combined with bone graft ranked first (SUCRA = 100.0%), demonstrating a statistically significant reduction in VAS scores (MD = −3.57, 95% CrI: −4.74 to −2.40). Tantalum rods alone ranked second (SUCRA = 85.7%; MD = −1.88, 95% CrI: −2.43 to −1.32). Subsequent rankings for pain reduction included iliac autograft, vascularized fibular autograft, the without‐graft group, artificial bone, fibular autograft, and other autografts (Figure 4C–E). Restricting the analysis to RCTs yielded a similar pattern of relative effects and intervention rankings (Figure S5A–E). These findings indicate that tantalum rod‐based strategies, particularly when combined with bone grafting, may provide more favorable pain control. Prognostic Analysis of Necrosis Staging Maintained(NSM) Necrosis Staging Maintained (NSM) was defined as no progression in ARCO or Ficat stage from baseline to follow‐up. The Bayesian random‐effects network meta‐analysis showed no significant differences among the included filler strategies (Figure 5A,B). Network meta‐analysis of bone defect filler strategies based on necrosis staging maintained at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. For necrosis stage maintenance (NSM), although allograft demonstrated a high probabilistic ranking (SUCRA = 90.5%, OR = 0.29, 95% CrI: 0.02–3.60), the primary finding was a lack of statistically significant differences across the evaluated interventions. Because the credible intervals for almost all subsequent pairwise comparisons broadly crossed the null value (1.0), the specific hierarchical order does not translate to definitive clinical superiority. These findings suggest that the various bone defect filler strategies have a comparable baseline effect on preventing disease progression (Figure 5C–E). Restricting the analysis to RCTs similarly showed no significant differences among intervention strategies, yielding comparable relative effect (Figure S6A–E). Prognostic Analysis of Radiographic Progression(RP) Radiographic progression (RP) was defined as femoral head collapse detected on imaging at the final follow‐up [36]. As an important radiographic endpoint after hip‐preserving surgery, RP reflects structural failure after treatment. The network structure and pairwise comparisons are shown in Figure 6A,B. The Bayesian random‐effects network meta‐analysis showed that iliac autograft with screw fixation was associated with a lower risk of radiographic failure than artificial bone. Network meta‐analysis of bone defect filler strategies based on radiographic progression at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. For the prevention of radiographic progression (RP), iliac autograft combined with screw fixation ranked first (SUCRA = 97.7%; OR = 4.83, 95% CrI: 0.65–35.8). However, the primary finding is the comparable performance across all interventions. Without statistically significant pairwise differences, these diverse grafting strategies appear to provide similar baseline structural preservation. Although the top ranking hints at a potential mechanical benefit of adding screw fixation, this probabilistic trend lacks statistical support and remains inconclusive (Figure 6C–E). Furthermore, sensitivity analysis restricted to RCTs yielded broadly similar results, confirming the absence of significant treatment variations (Figure S7A–E). Prognostic Analysis of Receive Total Hip Arthroplasty(RTHA) Receiving total hip arthroplasty (RTHA) was regarded as clinical failure [37]. The criteria for THA conversion generally included femoral head collapse, impaired hip function, and persistent severe pain despite oral analgesic treatment for at least 1 month. The Bayesian random‐effects network meta‐analysis showed that tantalum rods alone were associated with a higher rate of RTHA than other filler strategies (Figure 7A,B). Network meta‐analysis of bone defect filler strategies based on RTHA at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. For long‐term joint survivorship (avoiding THA conversion), artificial bone combined with iliac autograft ranked first (SUCRA = 89.3%). Intermediate rankings included iliac autograft with screw fixation, vascularized fibular autograft, other autografts combined with vascularized greater trochanter graft, iliac autograft, and artificial bone. Conversely, tantalum rods alone (SUCRA = 12.8%) and other autografts (SUCRA = 12.6%) ranked lowest. Compared to the top‐ranked combination strategy, these standalone approaches exhibited significantly lower odds of success (tantalum rods: OR = 0.03, 95% CrI: 0.00–0.71; other autografts: OR = 0.05, 95% CrI: 0.00 to 0.51). Overall, this probabilistic trend suggests that combination strategies may offer more durable hip preservation than standalone tantalum rods or simple autografts (Figure 7C–E). Discussion Principal Findings Our analysis of 14 reconstructive strategies shows no single filler material universally excels across all outcomes. Tantalum rods with bone grafts provided early functional and analgesic benefits, but standalone rods increased THA conversion risk. For structural preservation, screw‐fixated iliac autografts best delayed radiographic progression, while combining artificial and iliac autogenous bone maximized long‐term joint survivorship. These varied profiles underscore the need for individualized surgical planning, favoring composite strategies that balance mechanical stability with biological repair. Biological and Biomechanical Interpretation Guided by the concept of “function determines structure” in trabecular microarchitecture [38, 39], this network meta‐analysis compared 14 bone defect filler strategies following lesion debridement for ONFH. To preserve the specific biological and biomechanical characteristics of each surgical technique and to minimize intra‐node clinical heterogeneity, these strategies were evaluated as independent nodes rather than being grouped into broader macro‐categories. The main finding was that no single filler material showed consistent superiority across functional recovery, pain relief, necrosis stage maintenance, radiographic progression, and conversion to THA. Importantly, this absence of a universally superior material is not merely a statistical finding; it reflects the biological and mechanical complexity of femoral head repair after debridement. Lesion debridement does not simply remove necrotic bone; it also creates an intraosseous defect that requires reconstruction. Therefore, effective hip preservation requires both immediate mechanical stability to resist subchondral collapse and a biologically favorable environment for vascular ingrowth and bone remodeling [40, 41]. From this perspective, this study extends the interpretation of filler selection from simple defect filling to intraosseous reconstruction. Among the included strategies, tantalum rod‐based treatments showed a distinct but complex profile. Tantalum rods combined with bone graft ranked favorably for both Harris Hip Score and Visual Analogue Scale, suggesting potential benefits in functional recovery and pain relief. This may be explained by the mechanical properties of tantalum, which can provide early structural reinforcement and load transfer within the femoral head [42]. However, this early symptomatic advantage did not necessarily translate into long‐term hip preservation [43]. In particular, tantalum rods alone were associated with a higher rate of conversion to THA. This discrepancy suggests that mechanical support alone may be insufficient when biological reconstruction of the necrotic cavity is inadequate. A single rod may not fully cover the necrotic region, and limited bone ingrowth may reduce its long‐term protective effect [44, 45]. Thus, early pain relief or functional improvement should not be interpreted as definitive evidence of durable structural preservation. This dissociation between symptomatic improvement and structural failure indicates that HHS or VAS improvement alone should not be used to judge the long‐term success of a filler strategy. In contrast, bone graft‐based and combined strategies appeared to address different aspects of intraosseous reconstruction. Allograft ranked favorably for early function and necrosis stage maintenance, indicating that it may provide structural support while avoiding donor‐site morbidity. However, its biological repair capacity may be limited compared with autologous grafts. Iliac autograft with screw fixation ranked highest for preventing radiographic progression, suggesting that additional fixation may enhance graft stability and help resist collapse during the early healing period. More importantly, artificial bone combined with iliac autograft ranked highest for avoiding THA conversion. This result supports the value of combining complementary material properties: artificial bone may provide an osteoconductive scaffold, whereas autologous iliac bone contributes osteogenic potential. Taken together, these findings suggest that the most promising strategies are not necessarily those with the strongest single function, but those that combine complementary mechanical and biological effects to meet the dual requirements of intraosseous reconstruction. Clinical Implications Accordingly, the clinical interpretation of these findings should not rely on one outcome or one ranking alone. Filler selection after lesion debridement should be individualized according to necrosis stage, lesion size, lesion location, collapse risk, and the expected balance between mechanical support and biological repair. For larger defects or lesions with higher collapse risk, strategies that enhance structural stability may be more appropriate. For early‐stage lesions with greater potential for repair, graft‐based or biologically active combined materials may be preferred. When both support and regeneration are required, combined strategies may offer a more balanced option. Therefore, clinical decision‐making should integrate radiographic characteristics, intraoperative defect morphology, and patient‐specific functional demands rather than treating all ONFH lesions as a uniform condition. Limitations Several limitations should be considered when interpreting these results. First, the inclusion of only 18 studies resulted in small sample sizes for certain intervention groups, which may reduce the stability of treatment estimates. Second, unavoidable heterogeneity exists across the primary literature. Although major clinical variables were comparable, studies differed in necrosis stages, surgical approaches, debridement methods, and rehabilitation protocols. Additionally, inconsistent reporting prevented subgroup analyses for critical prognostic factors, such as exact defect volumes, collapse severity, and lesion locations (e.g., JIC classification). Third, the median follow‐up duration was relatively short. Studies evaluating radiographic progression or THA conversion beyond 36 months were scarce. Because these failure endpoints are time‐cumulative, long‐term joint survivorship requires further validation. Fourth, our findings depend on primary study quality, and selection bias may be present in the non‐randomized comparative trials. Fifth, publication bias could not be formally assessed because the evidence network was sparse and each direct comparison included few studies. Sixth, some patients had bilateral disease, contributing two hips to the analysis. Since primary studies lacked intra‐patient correlation metrics, within‐patient cluster effects could not be adjusted. While this does not bias the point estimates, it may cause slight overprecision in the credible intervals. Ultimately, future large‐scale, multicenter randomized trials with standardized protocols and long‐term follow‐up are needed to validate these findings. Conclusion Based on the concept of intraosseous reconstruction in hip‐preserving surgery, this network meta‐analysis indicates that the choice of bone defect filler material after lesion debridement plays an important role in functional recovery and long‐term prognosis in ONFH. Tantalum rods combined with bone graft showed relative advantages in postoperative pain relief and functional recovery, whereas the higher risk of conversion to THA associated with tantalum rods alone should be carefully considered. Allograft showed a favorable profile for necrosis stage maintenance, while iliac autograft with screw fixation demonstrated potential in delaying radiographic progression. Artificial bone combined with iliac autograft ranked highest for avoiding THA conversion, suggesting a more balanced strategy that integrates structural support with biological repair. Overall, these findings support the use of combined filler strategies when both mechanical stability and osteobiological reconstruction are required. Further large‐scale, multicenter randomized trials with long‐term follow‐up are needed to validate these findings and provide more reliable evidence for material selection in ONFH. Author Contributions Zukang Miao: conceptualization, methodology, writing – original draft, data curation, supervision, writing – review and editing. Zhiwei Pei: writing – original draft, software, data curation. Bing Wang: writing – original draft. Zemeng Hou: data curation, supervision. Jingkun Jia: data curation, supervision. Junfei Zhao: data curation, supervision. Jing Dai: data curation, supervision. Xiaolei Sun: conceptualization, methodology, writing – review and editing. Xinlong Ma: conceptualization, methodology, writing – review and editing, funding acquisition. Funding This work was supported by the National Key Research and Development Program of China (No. 2022YFC3601900), National Natural Science Foundation of China (No. 82572860), Clinical Collaboration Project for Major and Complex Diseases Integrating Chinese and Western Medicine (No. ZDYN‐2024‐B‐042), National Key Clinical Specialty Construction Project (Digital Orthopedic Diagnosis and Treatment Center). Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Quality and risk of bias assessment of included studies. (A) Summary plot generated using the Cochrane Risk of Bias tool for Randomized Controlled Trials (RoB 2.0); (B) Traffic‐light plot generated using the Cochrane Risk of Bias tool for Randomized Controlled Trials (RoB 2.0). Figure S2: Network meta‐analysis of bone defect filler strategies based on RCTs only for HHS at 6‐month follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. Figure S3: Network meta‐analysis of bone defect filler strategies based on RCTs only for HHS at 1‐year follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. Figure S4: Network meta‐analysis of bone defect filler strategies based on HHS at 1‐year follow‐up. Local inconsistency analysis plot. Figure S5: Network meta‐analysis of bone defect filler strategies based on RCTs only for VAS at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. Figure S6: Network meta‐analysis of bone defect filler strategies based on RCTs only for Necrosis Staging Maintained at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. Figure S7: Network meta‐analysis of bone defect filler strategies based on RCTs only for radiographic progression at final follow‐up. (A) Network evidence plot. (B) Forest plot of pairwise comparisons. (C) Intervention ranking plot. (D) Rank probability plot. (E) Cumulative ranking probability plot. Table S1: The basic characteristics of all included studies. Table S2: A detailed assessment of quality and risk of bias. Table S3: The baseline distribution of effect modifiers across all 14 intervention categories.